期刊文献+

原发性肝癌基础研究及临床治疗的热点问题 被引量:7

原文传递
导出
摘要 我国肝细胞癌(以下简称肝癌)发病率与死亡率居世界首位,在我国是第2位的癌症杀手,全球第3位癌症死因。近年来,肝癌治疗领域出现了许多重大进展,包括肝癌的分子学分期、新型肿瘤标志物的发现、分子靶向药物的开发应用、对循证医学观念的重视、综合治疗模式的更新等。现将肝癌基础研究及临床治疗领域出现的若干热点问题及进展进行评述。
作者 樊嘉 王征
出处 《中华普通外科杂志》 CSCD 北大核心 2009年第10期777-779,共3页 Chinese Journal of General Surgery
  • 相关文献

参考文献16

  • 1Mahadevan D,Von Hoff DD.Tumor-stroma interactions in pancreatic ductal adenocarcinoma.Mol Caneer Ther,2007,6:1186-1197. 被引量:1
  • 2Gao Q,Qiu SJ,Fan J,et al.Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.J Clin Oncol,2007,25:2586-2593. 被引量:1
  • 3Cai MY,Xu YF,Qiu SJ,et al.Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection.Clin Cancer Res,2009,15:4686-4893. 被引量:1
  • 4Reya T,Morrison SJ,Clarke MP,et al.Stem cells,cancer,and cancer stem cells.Nature,2001,414:105-111. 被引量:1
  • 5Chiba T,Kita K,Zheng YW,et al.Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties.Hepatology,2006,44:240-251. 被引量:1
  • 6Yin S,Li J,Hu C,et al.CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.Int J Cancer,2007,120:1444-1450. 被引量:1
  • 7Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med,2008,359:378-390. 被引量:1
  • 8Kerbel RS.Antiangiogenic therapy;a universal chemosensitization strategy for cancer? Science,2006,312:1171-1175. 被引量:1
  • 9Jubh AM,Oates AJ,Holden S,et al.Predicting benefit from anti-angiogenic agents in malignancy.Nat Rev Cancer,2006,6:626-635. 被引量:1
  • 10Steeg PS.Angiogenesis inhibitors;motivators of metastasis?Nature Med,2003,9:822-823. 被引量:1

二级参考文献1

共引文献63

同被引文献42

  • 1Marcello Donati,Gregor A Stavrou,Karl J Oldhafer.Current position of ALPPS in the surgical landscape of CRLM treatment proposals[J].World Journal of Gastroenterology,2013,19(39):6548-6554. 被引量:16
  • 2汤钊猷.肝癌外科若干问题的我见[J].中华肝胆外科杂志,2006,12(2):73-74. 被引量:10
  • 3DUFFY J P,HIATT J R,BUSUTTIL R W.Surgical resection of hepatocellular carcinoma[J].Cancer J,2008,14(2):100-110. 被引量:1
  • 4SHAH S A,CLEARY S P,WEI A C,et al.Recurrence after liverresection for hepatocellular carcionma risk factors,treatment,and outcomes[J].Surgery,2007,141(3):330-333. 被引量:1
  • 5LLOVET J M,SCHWARTZ M,MAZZAFERRO V.Resection and liver transplantation for hepatocellular carcinoma[J].Semin Liver Dis,2005,25(2):181-200. 被引量:1
  • 6IMAMURA H,MATSUYAMA Y,TANAKA E,et al.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcionma after hepatectomy[J].J Hepatol,2003,38(2):200-207. 被引量:1
  • 7HOSAKA T,IKEDA K,KOBAYASHI M,et al.Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma[J].Liver Int,2009,29(5):736-742. 被引量:1
  • 8Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res, 2006, 12:5423-5434. 被引量:1
  • 9Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T ceils enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol, 2006, 24 : 5373- 5380. 被引量:1
  • 10Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol, 2007, 8:457-462. 被引量:1

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部